Table 2 Subgroup analysis of LVEF change
Variable | No. of trials | MD[95% CI] | Heterogeneity (I2) (%) | P-value |
|---|---|---|---|---|
Follow-up for examining LVEF (months) | ||||
> 6 | 10 | 3.54 [0.91, 6.17] | 79 | 0.79 |
≤ 6 | 12 | 4.10 [0.92, 7.28] | 81 | |
Method of measurement | ||||
ECHO | 8 | 6.39 [3.71, 9.08] | 84 | 0.05 |
MRI | 12 | 1.80 [−0.77, 4.36] | 55 | |
SPECT | 2 | 2.93 [−7.41,13.28] | 90 | |
Type of stem cells | ||||
BMMNC/BMC | 14 | 3.84 [1.28, 6.40] | 75 | 0.82 |
CD133 + /CD34 + | 7 | 3.29 [−0.58, 7.16] | 89 | |
Route of cell administration | ||||
IM | 18 | 3.80 [1.53, 6.06] | 84 | 0.48 |
IC | 3 | 5.07 [2.34, 7.80] | 0 | |
Amount of stem cells administered | ||||
≥ 108 | 8 | 3.78 [0.52, 7.03] | 77 | 0.57 |
< 108 | 8 | 5.34 [1.05, 9.63] | 84 | |
Baseline LVEF (%) | ||||
< 30 | 6 | 3.97 [−0.68, 8.62] | 87 | 0.94 |
≥ 30 | 16 | 3.78 [1.58, 5.99] | 77 | |